{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:03:23Z","timestamp":1773173003295,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.yexmp.2016.04.002","type":"journal-article","created":{"date-parts":[[2016,4,17]],"date-time":"2016-04-17T18:46:30Z","timestamp":1460918790000},"page":"421-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers"],"prefix":"10.1016","volume":"100","author":[{"given":"Kristen E.","family":"Muller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Marotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine B.","family":"de Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary D.","family":"Chamberlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Tsongalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Tafe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2016.04.002_bb0010","series-title":"HER2 (ERBB2) in breast cancer","author":"Balko","year":"2013"},{"key":"10.1016\/j.yexmp.2016.04.002_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/cge.12381","article-title":"Personalized therapy for breast cancer","volume":"86","author":"De Abreu","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0025","first-page":"252","article-title":"Cancer treatment and survivorship statistics","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0035","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3892\/or.2014.3346","article-title":"Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients","volume":"32","author":"Dobes","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature09807","article-title":"Tumour evolution inferred by single-cell sequencing","volume":"472","author":"Navin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2016.04.002_bb0055","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2016.04.002_bb0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCPWDEQYCYC92JQ","article-title":"Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing","volume":"144","author":"Roy-Chowdhuri","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0065","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0070","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1634\/theoncologist.2015-0097","article-title":"Implementation of a molecular tumor board: the impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center","volume":"20","author":"Tafe","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.yexmp.2016.04.002_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2016.04.002_bb0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1515\/cclm-2013-0883","article-title":"Routine use of the ion torrent AmpliSeq\u2122 cancer hotspot panel for identification of clinically actionable somatic mutations","volume":"52","author":"Tsongalis","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0085","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline","volume":"33","author":"Van Poznak","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2013.06.002","article-title":"Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks","volume":"23","author":"Wang","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/path.2648","article-title":"The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade","volume":"220","author":"Weigelt","year":"2010","journal-title":"J. Pathol."},{"key":"10.1016\/j.yexmp.2016.04.002_bb0100","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.18632\/oncotarget.1946","article-title":"Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms","volume":"5","author":"Wheler","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexmp.2016.04.002_bb0105","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/bjc.2014.341","article-title":"The AURORA initiative for metastatic breast cancer","volume":"111","author":"Zardavas","year":"2014","journal-title":"Br. J. Cancer"}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480016300375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480016300375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T02:44:39Z","timestamp":1757990679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480016300375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0014480016300375"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2016.04.002","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2016.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}